Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85
Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $82 to $85.
Read original at benzingaStocks · News reference
RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 6:38 PM
- Checked
- Aug 7, 2026, 6:38 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85
Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $82 to $85.
Read original at benzingaCG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K Estimate
CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.67) by 34.33 percent. This is a 66.67 percent decrease over losses of $(0.54) per share from
Read original at benzinga